ZAI LAB LIMITED Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ZAI LAB LIMITED stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.03M, a 86.64% decline year-over-year.
- ZAI LAB LIMITED stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $833.00K, a 77.69% decline year-over-year.
- ZAI LAB LIMITED stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $2.14M, a 25.30% decline year-over-year.
- ZAI LAB LIMITED stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $7.72M, a 17440.91% increase year-over-year.
- ZAI LAB LIMITED stock issued during period, value, stock options exercised for fiscal 2025 was $13.60M, a 316.15% increase from fiscal 2024.
- ZAI LAB LIMITED stock issued during period, value, stock options exercised for fiscal 2024 was $3.27M, a 28.30% increase from fiscal 2023.
- ZAI LAB LIMITED stock issued during period, value, stock options exercised for fiscal 2023 was $2.55M, a 56.59% decline from fiscal 2022.
- ZAI LAB LIMITED stock issued during period, value, stock options exercised for fiscal 2022 was $5.87M, a 20.86% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.03M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $833.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $13.60M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $2.14M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $7.72M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $3.73M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $3.27M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.87M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $44.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.55M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $317.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $88.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $1.67M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $5.87M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $1.05M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $4.32M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $297.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $7.42M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $2.92M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $3.29M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $702.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $6.66M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $1.01M 10-Q · filed 2021-11-09 | $4.69M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $2.73M 10-Q · filed 2021-11-09 | $3.83M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $346.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $607.63K derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $1.05M 10-K · filed 2022-03-01 |
| 2019-09-30 | $143.37K derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | |
| 2018-12-31 | $163.22K derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $196.00K 10-K · filed 2021-03-01 |
| 2017-12-31 | $65.00K 20-F · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |